Encorafenib: Global Drug Analysis 2017 with Forecasts to 2026 - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: Encorafenib" drug pipelines has been added to ResearchAndMarkets.com's offering.

Encorafenib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is a RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E. The drug was developed with the hypothesis that a more potent RAF inhibitor with superior pharmacological properties would maximize the degree and duration of patient response. In preclinical studies, oral dosing of encorafenib resulted in potent and sustained inhibition of the RAS/RAF/MEK/ERK pathway.

It is believed that, because half of microsatellite instability-high (MSI-H) tumors also harbor mutations in BRAF, the combination of binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical), encorafenib, and Erbitux (cetuximab; Eli Lilly/Merck KGaA) has the potential to compete with the programmed death-1 (PD-1) inhibitors currently approved for MSI-H patients. However, Array BioPharma will have to demonstrate that the triple regimen is cost-effective and safe in order to make in-roads in this crowded market.

Key Topics Covered:

Product Profiles
Encorafenib: Colorectal cancer (CRC)
Encorafenib: Melanoma

List of Figures
Figure 1: Encorafenib for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary for encorafenib in colorectal cancer
Figure 3: Drug assessment summary for encorafenib in colorectal cancer
Figure 4: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
Figure 5: Encorafenib for melanoma - SWOT analysis
Figure 6: Drug assessment summary of encorafenib in melanoma

List of Tables
Table 1: Encorafenib drug profile
Table 2: Encorafenib Phase III data in colorectal cancer
Table 3: Encorafenib Phase II data in colorectal cancer
Table 4: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
Table 5: Patients treated with encorafenib across the US and five major EU markets, by country, 2016-25
Table 6: Encorafenib drug profile
Table 7: Encorafenib Phase III trial in melanoma
Table 8: Binimetinib and encorafenib combination Phase II trial data in melanoma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5d8lst/encorafenib?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Skin Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Skin Cancer Drugs